Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

COMPLETED Phase 1

Human Mesenchymal Stem Cells For Acute Respiratory Distress Syndrome

NCT01775774 · View on ClinicalTrials.gov ↗

Study Summary

This is a Phase 1, open label, dose escalation, multi-center clinical trial of Allogeneic Bone Marrow-Derived Human Mesenchymal Stem Cells (hMSCs) for the treatment of Acute Respiratory Distress Syndrome (ARDS). The purpose of this study is to assess the safety of hMSCs in patients with ARDS.

Interventions

  • BIOLOGICAL Allogeneic Bone Marrow-Derived Human Mesenchymal Stem Cells

Study Locations (4)

California

  • University of California San Francisco Medical Center — San Francisco
  • Stanford University Medical Center — Stanford

Massachusetts

  • Massachusetts General Hospital — Boston

Pennsylvania

  • University of Pittsburgh Medical Center — Pittsburgh

Trial Details

FieldValue
Enrollment Target 9 participants
Start Date 2013-07
Est. Completion 2015-02
Phase Phase 1

Sponsor

Michael A. Matthay

1 total trials

Interested in This Trial?

Always speak with your doctor before enrolling in a clinical trial.

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT01775774

The ClinicalTrials.gov registry entry for NCT01775774 describes a study currently listed as completed. It is categorized as Phase 1, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 9 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Michael A. Matthay, which has 1 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.

The record links to 1 condition, with Acute Respiratory Distress Syndrome appearing as the primary indexed condition, and to 1 intervention — of which Allogeneic Bone Marrow-Derived Human Mesenchymal Stem Cells is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.

Geographic footprint matters for practical reasons: NCT01775774 reports 4 study locations spanning 3 distinct geographic areas — top geographies include California, Massachusetts, Pennsylvania. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.

Frequently Asked Questions

What is clinical trial NCT01775774 about?

NCT01775774 is a clinical study titled "Human Mesenchymal Stem Cells For Acute Respiratory Distress Syndrome". This is a Phase 1, open label, dose escalation, multi-center clinical trial of Allogeneic Bone Marrow-Derived Human Mesenchymal Stem Cells (hMSCs) for the treatment of Acute Respiratory Distress Syndrome (ARDS). The purpose of this study is to assess the safety of hMSCs in patients with ARDS.

What is the current status of trial NCT01775774?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 9 participants. The study started on 2013-07. Estimated completion is 2015-02.

What conditions does trial NCT01775774 study?

This clinical trial studies the following conditions: Acute Respiratory Distress Syndrome. These conditions were identified from the trial registry and reflect the primary focus areas of the research.

What interventions are being tested in trial NCT01775774?

The interventions under investigation include: Allogeneic Bone Marrow-Derived Human Mesenchymal Stem Cells (BIOLOGICAL). Each intervention is being evaluated for safety and efficacy as part of this clinical study.

Who is sponsoring clinical trial NCT01775774?

This trial is sponsored by Michael A. Matthay, which has 1 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.

Where is trial NCT01775774 being conducted?

This trial has 4 study locations across California, Massachusetts, Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Related

Data sourced from official U.S. government datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial